Evidence-based absorption, distribution, metabolism, excretion (ADME) and its interplay with alternative toxicity methods
Open accessThe DOI matches its Crossref record; 16 of the 16 references it cites were found in a registry or an index.
Abstract
ADME (absorption, distribution, metabolism, elimination) has rapidly evolved over the past two decades, creating a unique interdisciplinary interface between medicinal chemists, biologists, formulators, toxicologists, clinicians, and regulators across industries, but has advanced most rapidly in the pharmaceutical industry. The implementation of ADME profiling of drug candidates, in conjunction with biological efficacy and safety optimization, has dramatically reduced pharmacokinetic drug failures in clinical trials and has become a lingua franca between disciplines that are involved in drug development. This article briefly reviews the basics and current state-of-the-art of ADME and the major lessons from the pharmaceutical industry on its efficient use, points out the importance of defining ADME properties leading to toxicity across industries for safety and toxicity prediction of chemicals, and raises the issues of quality, reliability, and reproducibility of tests and inclusion of ADME under the umbrella of evidence-based toxicology. Increasingly, in vitro results are used to inform ADME assessments and computer modeling. The aspects of kinetics of substances in cellular models themselves, however, are still too often neglected. ADME information will play a critical role in establishing quantitative in vitro to in vivo extrapolations (QIVIVE), integrated testing strategies, and systems toxicology approaches.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The price of innovation: new estimates of drug development costs
DiMasi, J. A., Hansen, R. W., & Grabowski, H. G. (2003) · Journal of Health Economics · doi:10.1016/s0167-6296(02)00126-1 · Cited by 4,265
Can the pharmaceutical industry reduce attrition rates?
Kola, I., & Landis, J. (2004) · Nature Reviews Drug Discovery · doi:10.1038/nrd1470 · Cited by 4,167
Martignoni, M., Groothuis, G. M. M., & de Kanter, R. (2006) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1517/17425255.2.6.875 · Cited by 1,478
Phase II and Phase III attrition rates 2011–2012
Arrowsmith, J., & Miller, P. (2013) · Nature Reviews Drug Discovery · doi:10.1038/nrd4090 · Cited by 697
Are animal models predictive for humans?
Shanks, N., Greek, R., & Greek, J. (2009) · Philosophy, Ethics, and Humanities in Medicine · doi:10.1186/1747-5341-4-2 · Cited by 677
Organoid-on-a-chip and body-on-a-chip systems for drug screening and disease modeling
Skardal, A., Shupe, T., & Atala, A. (2016) · Drug Discovery Today · doi:10.1016/j.drudis.2016.07.003 · Cited by 512
Drug research: myths, hype and reality
Kubinyi, H. (2003) · Nature Reviews Drug Discovery · doi:10.1038/nrd1156 · Cited by 348
Rostami-Hodjegan, A. (2012) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.2012.65 · Cited by 331
Marx, U. (2016) · ALTEX · doi:10.14573/altex.1603161 · Cited by 295
Animal versus human oral drug bioavailability: Do they correlate?
Musther, H., Olivares-Morales, A., Hatley, O. J. D., Liu, B., & Rostami Hodjegan, A. (2014) · European Journal of Pharmaceutical Sciences · doi:10.1016/j.ejps.2013.08.018 · Cited by 211
Cited by
Tanbin, S., Ahmad Fuad, F. A., & Abdul Hamid, A. A. (2020) · BioTech · doi:10.3390/biotech10010001 · Cited by 413
Adverse outcome pathways: opportunities, limitations and open questions
Leist, M., Ghallab, A., Graepel, R., Marchan, R., Hassan, R., Bennekou, S. H., Limonciel, A., Vinken, M., Schildknecht, S., Waldmann, T., et al. (2017) · Archives of Toxicology · doi:10.1007/s00204-017-2045-3 · Cited by 394
Self-citationNanotechnology in healthcare, and its safety and environmental risks
Ma, X., Tian, Y., Yang, R., Wang, H., Allahou, L. W., Chang, J., Williams, G., Knowles, J. C., & Poma, A. (2024) · Journal of Nanobiotechnology · doi:10.1186/s12951-024-02901-x · Cited by 332
Pamies, D. (2018) · ALTEX · doi:10.14573/altex.1710081 · Cited by 127
Magkouta, S., Veroutis, D., Pousias, A., Papaspyropoulos, A., Pippa, N., Lougiakis, N., Kambas, K., Lagopati, N., Polyzou, A., Georgiou, M., et al. (2023) · Molecular Cell · doi:10.1016/j.molcel.2023.09.006 · Cited by 59
Molinski, S. V., Shahani, V. M., MacKinnon, S. S., Morayniss, L. D., Laforet, M., Woollard, G., Kurji, N., Sanchez, C. G., Wodak, S. J., & Windemuth, A. (2017) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2016.12.115 · Cited by 17
Metadata
- Authors
- Tsaioun, K.
- Venue
- ALTEX
- Publisher
- ALTEX Edition
- Published
- 2016
- Volume
- 33
- Issue
- 4
- Pages
- 343-358
- ISSN
- 0946-7785 (ISSN-L)
- 1868-596X
- OpenAlex
- W2546948247
- Cited by
- 131
- References
- 16
- FWCI
- 11.31
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.